Frontlight ResearchEarly access
Not yet recruitingPhase 3
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial
Key facts
- Who runs it
- Centre Hospitalier Regional Universitaire De Tours
- Where
- France7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 266 people, planned
- Started
- 23 Feb 2026
- Expected to end
- 23 May 2029
- Type of study
- Interventional
- Record updated
- 29 October 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Children between 1 month to 17 years and 6 months
- Participants covered by or entitled to French social security
- Informed consent, dated and signed, from the participant's legal representative(s). (The emergency inclusion procedure will be used if the legal representative(s) cannot be contacted. When the legal representative(s) and the patient are available and/or able to consent, informed consent from the participant’s legal representative(s)
- Ability for participant to comply with the requirements of the study
- Receiving sedation by benzodiazepines for less than 6 hours at the time of inclusion
Who cannot take part
- Patient already enrolled in the study previously
- Need for paralytic medication (neuromuscular blocker) at admission to PICU
- High-grade heart conduction disorder (Second or third-degree atrioventricular block)
- Intracranial hypertension
- Following cardiac surgery
- Pregnant or breastfeeding woman (positive pregnancy test for women of childbearing age)
- Patients under guardianship, curatorship or legal protection
- Palliative care on admission
- Significant bradycardia (cf table)
- Severe hepatic dysfunction (CHILD score C or worse) due to the hepatic metabolism of dexmedetomidine
- Expected duration of invasive mechanical ventilation inferior to 12 hours
- Hospitalized in a pediatric intensive care unit without computerized prescription software
- Study interventions contraindications
- Status epilepticus
- Sedation for more than 6 hours by benzodiazepines at the time of inclusion
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess if continuous intravenous infusion of dexmedetomidine is effective to reduce the prevalence of delirium in critically ill children, needing mechanical ventilation for more than 12 hours.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 29 October 2025